Publications

BibTex format

@article{Georgiopoulos:2016:10.3389/fphar.2016.00235,
author = {Georgiopoulos, G and Katsi, V and Oikonomou, D and Vamvakou, G and Koutli, E and Laina, A and Tsioufis, C and Nihoyannopoulos, P and Tousoulis, D},
doi = {10.3389/fphar.2016.00235},
journal = {Frontiers in Pharmacology},
title = {Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study},
url = {http://dx.doi.org/10.3389/fphar.2016.00235},
volume = {7},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). METHODS: Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients. RESULTS: AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme (ACE) inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. CONCLUSION: Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research.
AU  - Georgiopoulos,G
AU  - Katsi,V
AU  - Oikonomou,D
AU  - Vamvakou,G
AU  - Koutli,E
AU  - Laina,A
AU  - Tsioufis,C
AU  - Nihoyannopoulos,P
AU  - Tousoulis,D
DO  - 10.3389/fphar.2016.00235
PY  - 2016///
SN  - 1663-9812
TI  - Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study
T2  - Frontiers in Pharmacology
UR  - http://dx.doi.org/10.3389/fphar.2016.00235
UR  - http://hdl.handle.net/10044/1/39842
VL  - 7
ER  -

Download

ProfessorPetrosNihoyannopoulos

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)